Fate Therapeutics

Fate Therapeutics
Name	Fate Therapeutics
Foundation	2007
Location	San Diego, California, United States
Key people	J. Scott Wolchko (President & CEO)
Industry	Biotechnology
Products	Cell therapies for cancer and immune disorders
Website	https://www.fatetherapeutics.com

Fate Therapeutics. It is a clinical-stage biotechnology company pioneering the development of programmed cellular immunotherapies for patients with cancer and immune disorders. Founded in 2007 and headquartered in San Diego, the company leverages its proprietary induced pluripotent stem cell platform to create off-the-shelf, or allogeneic, cell products. Its scientific approach aims to overcome key limitations of autologous cell therapies, such as manufacturing complexity and patient wait times, by engineering master iPSC lines that can be expanded and differentiated into consistent, dose-controlled therapeutic cells.

Company Overview

The company was established to exploit breakthroughs in stem cell biology and synthetic biology for therapeutic development. Its corporate strategy focuses on creating a deep pipeline of off-the-shelf cell therapies derived from clonal master induced pluripotent stem cell lines. Operations are centered at its state-of-the-art manufacturing and research facilities in San Diego and Seattle. As a publicly traded entity, it is listed on the NASDAQ under the ticker symbol "FATE" and is a constituent of several biotechnology indices. The company's mission is to deliver transformative treatments that are readily available to a broad patient population, moving beyond the personalized model of early CAR-T therapies pioneered by companies like Novartis and Kite Pharma.

Technology and Platforms

The core of its innovation is the FTiPS Platform, which involves engineering master induced pluripotent stem cell lines with multiple transgenes to direct their differentiation into specific immune cell types. Key platform technologies include the FT819 program, a CAR-T product candidate derived from a master iPSC line, and the FT596 program, which incorporates a CAR, a T-cell receptor, and IL-15 for enhanced anti-tumor activity. The company utilizes advanced gene editing techniques, including CRISPR and TALEN technologies, to precisely modify cells. These platforms are designed to produce NK cells and T cells with improved persistence, tumor targeting, and resistance to the host immune system, addressing challenges seen in earlier allogeneic approaches.

Clinical Pipeline

Its clinical-stage assets include several investigational products being evaluated in hematologic malignancies and solid tumors. The lead CAR-T candidate, FT819, is in Phase 1 trials for B-cell lymphoma and leukemia. The FT596 program, targeting CD19-positive cancers, is also in ongoing clinical studies. For multiple myeloma, the FT576 program incorporates a BCMA-targeting CAR and is being developed as a monotherapy and in combination with CD38-targeting monoclonal antibodies like daratumumab. Additional pipeline candidates include FT825 for HER2-expressing solid tumors and FT522 for autoimmune diseases. These trials are conducted at major academic centers including the University of Texas MD Anderson Cancer Center and the Mayo Clinic.

Collaborations and Partnerships

The company has established several high-profile strategic alliances to advance its technology and pipeline. A major multi-product collaboration with Janssen Biotech, a division of Johnson & Johnson, focuses on developing CAR-NK and CAR-T cell therapies for cancer. Another significant partnership with ONO Pharmaceutical of Japan is centered on developing novel iPSC-derived cell therapies. The company also entered into a collaboration with the University of California, San Diego for foundational stem cell research. These partnerships often include upfront payments, milestone-based funding, and shared development responsibilities, providing non-dilutive capital and validation of its platform.

Financial and Corporate History

Following its initial incorporation in 2007, the company completed its initial public offering on the NASDAQ in 2013. Major financing milestones include a strategic equity investment from Juno Therapeutics in 2015 and significant funding from its collaboration agreements with Janssen and ONO Pharmaceutical. In 2021, it announced a strategic restructuring to prioritize its clinical programs, which included a reduction in workforce. The company's financials are characterized by significant investment in research and development, funded through equity offerings, partnership revenues, and its cash reserves, as it advances multiple programs through costly clinical trials.

Leadership and Governance

The company is led by President and Chief Executive Officer J. Scott Wolchko, who has held the position since 2014. The executive team includes senior leaders with extensive experience from organizations like Biogen, Amgen, and Celgene. The Board of Directors is chaired by Robert Hershberg, formerly of Celgene, and includes other notable figures from the biopharmaceutical industry such as Cindy Jacobs. The leadership has guided the company's strategic direction, focusing on platform validation through clinical data and securing key alliances to build long-term value in the competitive cell therapy landscape.

Category:Biotechnology companies of the United States Category:Companies based in San Diego Category:Companies listed on NASDAQ